Status:
RECRUITING
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
Lead Sponsor:
Universidade do Porto
Collaborating Sponsors:
INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.
Unidade de Farmacovigilância do Porto
Conditions:
Inflammatory Disease
Drug Side Effect
Eligibility:
All Genders
18+ years
Brief Summary
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid ...
Detailed Description
The LOOK-UP study is an investigator-initiated clinical study conducted by INFARMED, the Portuguese Authority of Medicines and Health Products, I.P., and coordinated by the Porto Pharmacovigilance Cen...
Eligibility Criteria
Inclusion
- Prescription of Rinvoq™ from January 1, 2024;
- 18 years of age or older at the time of recruitment; and
- Expressed consent to participate in the study.
Exclusion
- They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;
- They are participating in a phase I, II, or III clinical trial;
- They have a life expectancy of less than 1 month; or
- They do not have a valid telephone contact.
Key Trial Info
Start Date :
July 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06498167
Start Date
July 1 2024
End Date
December 31 2024
Last Update
July 15 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Unidade Local de Saúde de Santo António, E.P.E.
Porto, Portugal, 4050-366
2
Unidade Local de Saúde de São João, E.P.E.
Porto, Portugal, 4200-319
3
Unidade Local de Saúde de Gaia/Espinho, E.P.E.
Porto, Portugal, 4434-502